Determination of chlorpheniramine in human plasma by HPLC-ESI-MS/MS: Application to a dexchlorpheniramine comparative bioavailability study

Biomedical Chromatography

Volumn 24, Issue 7, 2010, Pages 774-781

  Moreno, Ronilson Agnaldo ^a,b   Oliveira Silva, Diogo ^c   Sverdloff, Carlos Eduardo ^a,b   Borges, Bruno Carter ^d   Galvinas, Paulo Alexandre Rebelo ^e   Astigarraga, Rafael Barrientos ^e   Borges, Ney Carter ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Synchrophar Assessoria e Desenvolvimento de Projetos Clinicos   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^e Magabi Pesquisas Clínicas e Farmacêuticas   (Brazil)

Author keywords

Bioequivalence; Chlorpheniramine; Dexchlorpheniramine quantification; Liquid chromatography tandem mass spectrometry; Pharmacokinetics; Plasma

Indexed keywords

AMMONIUM HYDROXIDE; BIOCHEMISTRY; DRUG PRODUCTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PLASMA (HUMAN);

BIOAVAILABILITY STUDY; BIOEQUIVALENCE; CHLORPHENIRAMINE; DEXCHLORPHENIRAMINE QUANTIFICATION; HPLC-ESI-MS/MS; HPLC/ESI-MS/MS; HUMAN PLASMAS; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY;

DICHLOROMETHANE;

BROMPHENIRAMINE; CELESTAMINE; CHLORPHENIRAMINE; DEXCHLORPHENIRAMINE MALEATE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG STABILITY; DRUG TOLERABILITY; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; TABLET;

EID: 77953512576     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1362     Document Type: Article

References (36)

1. ANVISA, Brazilian National Sanitary Surveillance Agency, Brazil. 2003. Athanikar NK, Peng GW, Nation RL, Huang SM and Chiou WL. Chlorpheniramine. I. Rapid quantitative analysis of chlorpheniramine in plasma, saliva and urine by high-performance liquid chromatography. Journal of Chromatography 1979; 162: 367-376.
2. Bonfi glio R, King RC, Olah TV and Merkle K. The eff ects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Communications in Mass Spectrometry 1999; 13: 1175-1185.
3. Burton WN, Conti DJ, Chen CY, Schultz AB and Edington DW. The impact of allergies and allergy treatment on worker productivity. Journal of Occupational and Environmental Medicine 2001; 43: 64-71.
4. Celma C, Allue JA, Prunonosa J, Peraire C and Obach R. Simultaneous determination of paracetamol and chlorpheniramine in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 2000; 870: 77-86. (Pubitemid 30077411)
5. Chen X, Zhang Y and Zhong D. Simultaneous determination of chlorpheniramine and pseudoephedrine in human plasma by liquid chromatography-tandem mass spectrometry. Biomedical Chromatography 2004; 18: 248-253. (Pubitemid 38801609)
6. Fried KM, Young AE, Usdin Yasuda S and Wainer IW. The enantioselective determination of chlorpheniramine and its major metabolites in human plasma using chiral chromatography on a beta-cyclodextrin chiral stationary phase and mass spectrometric detection. Journal of Pharmaceutical and Biomedical Analysis 2002; 27: 479-488. (Pubitemid 34076674)
7. Gilmore TM, Alexander BH, Mueller BA and Rivara FP. Occupational injuries and medication use. American Journal of Industrial Medicine 1996; 30: 234-239.
8. Hiep BT, Khanh V, Hung NK, Thuillier A and Gimenez F. Determination of the enantiomers of chlorpheniramine and its main monodesmethyl metabolite in urine using achiral-chiral liquid chromatography. Journal of Chromatography B: Biomedical Science Applications 1998; 707: 235-240.
9. Hindmarch and Shamsi Z. The eff ects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers. Current Medical Research Opinion 2001; 17: 273-281. (Pubitemid 34150436)
10. Kerns EH and Di L. Utility of mass spectrometry for pharmaceutical profi ling applications. Current Drug Metabolism 2006; 7: 457-466.
11. King R, Bonfi glio R, Fernandez-Metzler C, Miller-Stein C and Olah T. Mechanistic investigation of ionization suppression in electrospray ionization. Journal of the American Society for Mass Spectrometry 2000; 11: 942-950.
12. Koch KM, O'Connor-Semmes RL, Davis IM and Yin Y. Stereoselective pharmacokinetics of chlorpheniramine and the eff ect of ranitidine. Journal of Pharmaceutical Science 1998; 87: 1097-1100. (Pubitemid 28452110)
13. Marzo A and Dal Bo L. Tandem mass spectrometry (LC-MS-MS): a predominant role in bioassays for pharmacokinetic studies. Arzneimittel-Forschung - Drug Research 2007; 57: 122-128. (Pubitemid 46383953)
14. Masumoto K, Tashiro Y, Matsumoto K, Yoshida A, Hirayama M and Hayashi S. Simultaneous determination of codeine and chlorpheniramine in human plasma by capillary column gas chromatography. Journal of Chromatography 1986; 381: 323-329.
15. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix eff ect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
16. Maurer HH. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Analytical and Bioanalytical Chemistry 2007; 388: 1315-1325.
17. Miyamoto Y. Highly sensitive determination of chlorpheniramine as fl uorescence derivative by high-performance liquid chromatography. Journal of Chromatography 1987; 420: 63-72.
18. Moskowitz H and Burns M. Effects of terfenadine, diphenhydramine, and placebo on skills performance. Cutis 1988; 42: 14-18.
19. Muller C, Schafer P, Stortzel M, Vogt S and Weinmann W. Ion suppression eff ects in liquid chromatography-electrospray-ionisation transportregion collision induced dissociation mass spectrometry with diff erent serum extraction methods for systematic toxicological analysis with mass spectra libraries. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2002; 773: 47-52.
20. Nolen TM. Sedative eff ects of antihistamines: safety, performance, learning, and quality of life. Clinical Therapy 1997; 19: 39-55; discussion 32-33.
21. O'Hanlon JF and Ramaekers JG. Antihistamine eff ects on actual driving performance in a standard test: a summary of Dutch experience, 1989-94. Allergy 1995; 50: 234-242.
22. Passalacqua G, Bousquet J, Bachert C, Church MK, Bindsley-Jensen C, Nagy L, Szemere P, Davies RJ, Durham SR, Horak F, Kontou-Fili K, Malling HJ, van Cauwenberge P and Canonica GW. The clinical safety of H1-receptor antagonists. An EAACI position paper. Allergy 1996; 51: 666-675.
23. Rozet E, Ceccato A, Hubert C, Ziemons E, Oprean R, Rudaz S, Boulanger B and Hubert P. Analysis of recent pharmaceutical regulatory documents on analytical method validation. Journal of Chromatography A 2007; 1158: 111-125.
24. Shah VP. The history of bioanalytical method validation and regulation: evolution of a guidance document on bioanalytical methods validation. Aaps Journal 2007; 9: E43-E47.
25. Siegel C. The use of dexchlorpheniramine to treat nasal allergies. Current Therapy Research, Clinical and Experimental 1964; 6: 714-715.
26. Simons FE and Simons KJ. The pharmacology and use of H1-receptor- antagonist drugs. New England Journal of Medicine 1994; 330: 1663-1670.
27. Souverain S, Rudaz S and Veuthey JL. Matrix eff ect in LC-ESI-MS and LC-APCI-MS with off -line and on-line extraction procedures. Journal of Chromatography A 2004; 1058: 61-66. (Pubitemid 39487204)
28. Stokvis E, Rosing H and Beijnen JH. Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs. Mass Spectrometry Reviews 2005a; 24: 887-917. (Pubitemid 41641703)
29. Stokvis E, Rosing H and Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/ mass spectrometry: necessity or not? Rapid Communications in Mass Spectrometry 2005b; 19: 401-407. (Pubitemid 40203858)
30. Takagaki T, Matsuda M, Mizuki Y and Terauchi Y. Simple and sensitive method for the determination of chlorpheniramine maleate in human plasma using liquid chromatography-mass spectrometry. Journal of Chromatography B Analytical Technology in Biomedicine and Life Sciences 2002; 776: 169-176.
31. US-FDA. Guidance for Industry - Bioanalytical Method Validation. Food and Drug Administration, Center for Drug Evaluation and Research: Washington, DC, 2001.
32. Van Eeckhaut A, Detaevernier MR and Michotte Y. Development of a validated capillary electrophoresis method for enantiomeric purity testing of dexchlorpheniramine maleate. Journal of Chromatography A 2002; 958: 291-297. (Pubitemid 34556957)
33. Verster JC and Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffi c. Annals of Allergy and Asthma Immunology 2004; 92: 294-303; quiz 303-295, 355.
34. Viana NS Jr, Moreira-Campos LM and Vianna-Soares CD. Derivative ultraviolet spectrophotometric determination of dexchlorpheniramine maleate in tablets in presence of coloring agents. Farmaco 2005; 60: 900-905.
35. Xu RNX, Fan LM, Rieser MJ and El-Shourbagy TA. Recent advances in highthroughput quantitative bioanalysis by LC-MS/MS. Journal of Pharmaceutical and Biomedical Analysis 2007; 44: 342-355. (Pubitemid 46880094)
36. Zhong D, Chen X, Gu J, Li X and Guo J. Applications of liquid chromatography- tandem mass spectrometry in drug and biomedical analyses. Clinica Chimica Acta 2001; 313: 147-150. (Pubitemid 33016705)